Lotemax® was retro-metabolically designed to maintain efficacy while reducing the risk of
Unlike most other, commercially available ophthalmic steroids that have a ketone group at the C-20 position, Lotemax replaces this ketone with an ester group. This allows for rapid and predictable inactivation of unbound drug and reduced risk of significant IOP increase.1-3
Lotemax® is indicated to treat more ocular inflammatory conditions than any other topical ophthalmic corticosteroid on the market.
Lotemax has demonstrated efficacy in treating acute anterior uveitis, post operative inflammation, and giant papillary conjunctivitis.1
Lotemax® has a well-established safety profile with powerful anti-inflammatory activity
Lotemax provides a low risk of significant IOP elevations vs. Pred Forte (prednisolone acetate ophthalmic solution 1%). Lotemax has been shown to be three times less likely to increase IOP ≥10 mm Hg over baseline vs. Pred Forte.3,4
- In a summation of controlled, randomized studies of individuals treated for 28 days or longer with Lotemax, the incidence of significant elevation of IOP (≥10 mm Hg) was 2.1% (14/664) among patients receiving Lotemax and 6.7% (11/164) among patients receiving Pred Forte.